Effects of Mycophenolate Mofetil on Hematocrit after Renal Transplantation

Abstract

Get full access to this article

View all access options for this article.

References

Gaston

Julian

Curtis

. Posttransplant erythrocytosis: An enigma revisited. Am J Kidney Dis 1994;24: 1–11.

Nampoory

Johny

al-Hilali

Seshadri

Kanagasabhapathy

. Erythropoietin deficiency and relative resistance cause anemia in post-renal transplant recipients with normal renal function. Nephrol Dial Transplant 1996;11: 177–81.

Sunder-Plassmann

Horl

. Effect of erythropoietin on cardiovascular diseases. Am J Kidney Dis 2001;38(4 suppl 1):S20–5.

Qunibi

Barri

Devol

Al-Furayh

Sheth

Taher

. Factors predictive of post-transplant erythrocytosis. Kidney Int 1991;40: 1153–9.

Nutritional anaemias: report of a WHO Scientific Group. Geneva: World Health Organization, 1968.

Messinezy

Pearson

. The classification and diagnostic criteria of the erythrocytoses (polycythaemias). Clin Lab Haematol 1999;21: 309–16.

Cattaneo

Gaspari

Ferrari

Stucchi

Del Priorie

Perico

Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 2001;15: 402–9.

Hildner

Marker-Hermann

Schlaak

Becker

Germann

Schmitt

Azathioprine, mycophenolate mofetil, and methotrexate specifically modulate cytokine production by T cells. Ann N Y Acad Sci 1998;859: 204–7.

Means

Jr. Krantz

. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80: 1639–47.